NBP | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 7%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.45%

1 Month

6.70%

3 Months

-35.05%

6 Months

-48.38%

1 Year

194.33%

2 Year

32.78%

Key data

Stock price

$2.39

P/E Ratio

0.00

DAY RANGE

$2.38 - $2.47

EPS

N/A

52 WEEK RANGE

$0.83 - $6.79

52 WEEK CHANGE

$154.26

MARKET CAP

91.398 M

YIELD

N/A

SHARES OUTSTANDING

80.883 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-27-2025

BETA

1.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$335,717

AVERAGE 30 VOLUME

$858,665

Company detail

CEO: Xiu X. Zhu
Region: US
Website: i-mabbiopharma.com
Employees: 380
IPO year: 2020

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

I-Mab discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases. Its product candidates also includes Enoblituzumab, which has completed Phase 2 clinical trials for head and neck cancer, and other oncology diseases.

NBP - I-Mab